Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. - Wikidata - awgldk - TriplyDB

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

http://www.wikidata.org/entity/Q34131801

about

Transarterial radioembolization for hepatocellular carcinoma: a review Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives Treatment algorithms for managing hepatocellular carcinoma Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival.Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials.Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma.Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma.A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.Phage display creates innovative applications to combat hepatitis B virus Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma Liver cancer: Targeted future options Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma.Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.Molecular pathology of hepatic neoplasms: classification and clinical significance.Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice.Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study.Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Trans-arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium.Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

P2860

Q26738273-372439A7-0751-4E4C-892F-C09765E7F680 Q26767217-276D2942-E24A-45C6-B800-838681CBADCD Q26771776-BB4ED4FD-1D5C-46BF-997E-DEAD1791C1A1 Q26799745-CB42F86C-3B4B-44A5-B01D-37FC58A334ED Q26823575-50AA78ED-6E5C-4807-87C0-DA4A8F642085 Q26852174-1C7B4FB2-6FED-4F9E-B3F1-504225289AB1 Q27023616-66F46B28-05A8-4824-8251-98079DF30F8C Q27027923-030442A9-8E25-40A7-936A-06DE193587F2 Q28080514-59D20E10-5AE1-4F21-A66F-C8FF8107F55E Q28081783-B4CC202B-FD2B-4C9B-BE5E-AA04F12F8B38 Q28287609-B78F5552-A7C0-4FAF-9D24-27A5ACE0C03E Q30252965-872B992B-662E-463D-AFA4-B7D3806FCDD2 Q30845071-D2DE977A-8EDF-4918-9184-A87C9BFC64F1 Q31036824-8E70CF37-4557-476F-BA03-50FE636252ED Q33562782-C39EA3F5-6C3A-4B33-88E2-4B94FBC2D0F3 Q33631453-11976B52-B573-4130-BF7D-67AF97F52DA7 Q33820846-7E27005A-48EF-4BCC-9976-BBE18BD92BEB Q33845075-361B6A28-0BAC-473F-9162-0640492DBAC3 Q33900599-47DCCBB0-FE56-45D4-9F95-A02344B550E0 Q34126254-D552685D-A1B2-46C4-A6CE-079464760339 Q34137308-E1AED303-4B47-4264-8824-224B6C7DDA56 Q34221613-C98F12EF-6704-4566-9897-7719F9E74324 Q34362184-0255BFC5-CB56-466B-BFD9-44987AFA366A Q34483561-2211EE83-8DB3-4E6B-A111-DC1BAD05EB37 Q34681150-96A589DC-E369-482C-9493-28A74C4C2E56 Q34695180-BB6BE45A-DCF0-4D94-B63E-C3A45CB8239F Q34823616-BAF53C09-7510-4100-B9D0-D41C1C48D6CE Q34928923-69160543-78B0-4713-AB47-2801BE05B451 Q34954493-7ED14D61-B20C-43A3-A383-26D5F464A92F Q34975108-9E598ED3-5393-4031-846E-DAF726120170 Q35018711-E16C7665-601F-4AAF-B9CA-58E0B19A09AA Q35085486-BEF906AF-8E60-4B91-B848-4FCC10DE28F2 Q35308047-732D360C-E6CF-4980-9AC5-00BBC16368A3 Q35660038-6A8A59BA-D96F-405A-8465-74C89B46BAC2 Q35758190-3A5984DE-6BD6-46E5-8A7B-E1DF3FC3AED4 Q35759606-69453B93-5DF4-4006-B865-0E0753887CFE Q35776195-6A11F915-E180-4BF8-99B8-8CBB7464F843 Q35786517-8A069FBC-BD7D-4F8A-9ADF-EB54A1BAA999 Q35809482-B8045729-9F09-4BC7-B2DD-EAC4D7C65E62 Q35818336-E5FE1D36-BD26-47CF-A382-BACE5196B9DB

P2860

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

http://www.wikidata.org/entity/Q34131801

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@ast

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@en

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@nl

type

label

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@ast

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@en

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@nl

prefLabel

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@ast

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@en

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@nl

P1433

Q34131801-60482731-125B-4560-9B9D-A32023CE5162

P1476

Q34131801-46ECF745-A89C-41CC-A0AE-8F50308C5E1B

P2093

Q34131801-0445F145-86DF-48A0-85D7-48F4C13D93D5

Q34131801-0836E587-D467-482E-ACCC-F8123F60F451

Q34131801-1C4902BA-8A8D-4240-AE1B-872ACFF9E1EB

Q34131801-42223E62-DB7E-44BC-97F0-E42076483086

Q34131801-4EA662E1-55F0-4946-A37C-B722865E6836

Q34131801-5617FCA2-B2AD-4D3E-B2EC-0C6FE8AEC39D

Q34131801-59999CE9-841B-44D8-94F2-F6B49647B9E0

Q34131801-9415FCA2-37C7-41D4-B203-C675BBF972B7

Q34131801-9D3DF1DB-61BF-40B3-B8FB-9BFBE6EF867B

Q34131801-AD577803-D98B-47CF-BC96-9594E088961C

P2860

Q34131801-00B738CD-DE07-41CC-9290-87C9D65736E0

Q34131801-01EB193A-835F-4B3A-9DE7-8FBEF5D45788

Q34131801-07743436-B93F-474B-940F-E672CD34BEC0

Q34131801-0D098CB3-8BAE-4CA4-9083-8DC647C8A6A6

Q34131801-0D0F4B23-891C-4A76-80DB-C14ECABC48E4

Q34131801-1130DCC7-2D4D-4BDD-A3B4-0843BFB5C0AC

Q34131801-1276BC30-F87C-485B-8A57-8D0A1BA1212E

Q34131801-14408AB0-EEDA-4553-B3E4-B30D5099E550

Q34131801-15894A79-E202-4C1B-A184-5CBD7CADC1CD

Q34131801-160582FA-D433-4607-B2C0-FCCBDCCADA63

P304

Q34131801-06670D2A-DC09-46C9-B458-B4C98AACC007

P31

Q34131801-67401DC6-DB11-4D36-AE28-CAF363A35BAF

P356

Q34131801-7AA0603D-9A0D-41FD-91B0-35636028BAE2

P407

Q34131801-CCAAB2A1-86A6-42EF-A257-C14C7DD3AF8E

P433

Q34131801-4A5EFA5A-7667-4C92-AFE9-C5B48F25FCF9

P478

Q34131801-63AB441A-2D1F-40C9-A1D7-C3E5CB84120D

P50

Q34131801-7BCE7BA7-C8E9-48DA-B7E9-B1F8214963AE

Q34131801-EE237276-9054-4C83-A913-1F33FDE74E0B

P577

Q34131801-9E2190D4-E252-4E65-9561-548AEB94C9A7

P698

Q34131801-BEF00447-ED5E-4BD2-86E8-4D2D58DE9D20

P932

Q34131801-68EE9689-6D43-4B78-835F-B9E871AB6AE0

P356

JCO.2010.28.7805

P1433

Journal of Clinical Oncology

P1476

Hepatocellular carcinoma: cons ...... nical Trials Planning Meeting.

@en

P2093

Alan Venook

http://www.w3.org/2001/XMLSchema#string

Bert O'Neil

http://www.w3.org/2001/XMLSchema#string

Daniel Haller

http://www.w3.org/2001/XMLSchema#string

Deborah Jaffe

http://www.w3.org/2001/XMLSchema#string

Francis Yao

http://www.w3.org/2001/XMLSchema#string

Jacques Belghiti

http://www.w3.org/2001/XMLSchema#string

Joel Tepper

http://www.w3.org/2001/XMLSchema#string

Lawrence Schwartz

http://www.w3.org/2001/XMLSchema#string

Margaret Mooney

http://www.w3.org/2001/XMLSchema#string

Melanie B Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link

High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus.

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

P304

3994-4005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.28.7805

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Gregory J Gores

P577

2010-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20679622

http://www.w3.org/2001/XMLSchema#string

P932

2940397

http://www.w3.org/2001/XMLSchema#string